Partial Breast Re-irradiation for Breast Cancer

NCT06954623 · tracked via the Priya Life Science Germany tracker

Sponsor

University Hospital Heidelberg

Phase

Not applicable

Started

2025-08-28

Last updated

2026-03-10

Condition(s) studied

Breast Cancers

Investigational drug(s) / intervention(s)

Radiation Therapy

Radiation Therapy: proton beam radiation

Study summary

Breast cancer is the most common malignancy in women. Breast-conserving surgery (BCS) with adjuvant whole-breast irradiation (WBI) is currently the standard of care in the oncological treatment of primary breast cancer and offers an equivalent alternative to mastectomy. The primary aim of adjuvant radiotherapy (RT) is to improve local control and thus improve overall survival and breast cancer-specific mortality. However, nodal-negative women have a 10-year risk for local recurrences after RT in up to 15.6%. The management of ipsilateral breast cancer recurrence depends on the extent of tumor disease and staging results at the time of recurrence and mastectomy is currently the standard of care for previously irradiated patients. The application of particle therapy using proton beam therapy (PBT) represents an innovative radiotherapeutic technique for breast cancer patients. This trial will be conducted as a prospective single-arm phase II study in 20 patients with histologically proven invasive breast cancer recurrences with negative margins after repeat BCS and with an indication for local re-irradiation. Required time interval will be 1 year after previous RT to the ipsilateral breast. Patients will receive partial breast re-RT with proton beam therapy in 15 once daily fractions up to a total dose of 40.05 GyRBE. The primary endpoint is defined as the cumulative overall occurrence of acute / subacute skin toxicity grade ≥3 within 6 months after the start of re-RT.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * histologically confirmed recurrent (or new primary) ipsilateral invasive breast cancer or DCIS after prior RT of the ipsilateral breast * indication for re-irradiation after repeat breast conserving surgery (e.g. lumpectomy, wide excision, …) * tumor size \< 3 cm * clinically node-negative (cN0) * negative resection margin (R0) * time interval: start of re-RT to prior RT ≥ 12 months * ECOG Performance status ≤ 2 * ability of subject to understand character and individual consequences of the clinical trial * written informed consent * ≥18 years of age Exclusion Criteria: * distant metastases * concomitant chemotherapy (concomitant endocrine hormonal therapy is allowed; sequential chemotherapy is allowed) * patients who have not recovered from acute toxicities of prior therapies * known carcinoma \< 5 years ago (excluding Carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy * pregnant or lactating women * participation in another competing clinical study or observation period of competing trials * history of active connective tissue disorder (i.e. systemic lupus erythematosus, scleroderma, dermatomyositis, xeroderma pigmentosum, …) * medical implants, which are at the time of reirradiation not eligible for particle therapy at Heidelberg Ion Beam Therapy Center

Primary outcome measure(s)

skin toxicity — Within the first 6 months after the start of re-RT
Occurrence of overall acute / subacute skin toxicity CTCAE grade 3 or higher (NCI CTCAE version 5.0) assessed.

Trial sites (1)

Facility	City	Region	Status
University Hospital Heidelberg, Department Radiation Oncology	Heidelberg	Germany	Recruiting

More University Hospital Heidelberg trials in Germany

Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion Recruiting

Multi-professional Care Pathway and Network for the Promotion of Needs-oriented, Resident-oriented Exercise Therapy for Oncological Patients Recruiting

Clinical Performance of Long-span Fixed Partial Dentures Recruiting

Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location Active, not recruiting

Tumor-specific T Cells in Lung Cancer Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06954623 on ClinicalTrials.gov ↗ ← All trials in Germany